Matches 1 - 50 out of 113 1 2 3 >


Match Document Document Title
8178083 Treatment of optic neuritis  
The present invention provides a method for treating a patient having demyelinating optic neuritis (DON) comprising the sequential or simultaneous administration of a steroid compound and an...
8084419 Pharmaceutical compositions for sustained drug delivery  
Sustained delivery formulations comprising a water-insoluble complex of a peptide and a plurality of ligands are disclosed. The formulations of the invention allow for loading of high...
8044025 Urocortin proteins and uses thereof  
A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse cDNA was isolated from whole brain poly (A+) RNA that encodes a predicted...
7736653 Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier  
Disclosed is a novel use of an immunoglobulin Fc fragment, and more particularly, a pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier. The pharmaceutical composition...
7638138 Compositions for nasal administration of pharmaceuticals  
Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a...
7579013 Formulations for coated microprojections containing non-volatile counterions  
The invention provides for a formulation for coating one or more microprojections which reduces or minimizes the loss of counterions from the coating in order to achieve a pH-stabilized formulation.
7553872 Compounds and compositions for delivering active agents  
Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.
7524813 Selectively conjugated peptides and methods of making the same  
Methods for the selective conjugation of peptides which comprises an enzymatic incorporation of a functional group at the C-terminal end of a peptide followed by reaction with a second compound...
7378385 Role for GLP-1 to mediate responses to disparate stressors  
GLP-1 and GLP-1 receptor antagonists have been found to have a sedative or anxiolytic effect on the mammalian central nervous system. Conversely, GLP-1 and GLP-1 receptor agonists increase nervous...
7358225 Cloning and recombinant production of CRF receptor(s)  
In accordance with the present invention, there are provided novel G-protein-coupled receptor proteins (CRF-R) characterized by having sufficient binding affinity for corticotropin releasing factor...
7351741 Compounds and compositions for delivering active agents  
Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provide as well.
7285534 Corticotropin-releasing hormone analogs and their uses  
This invention provides members of the corticiotropin-releasing hormone superfamily and peptide analogs thereof wherein the 38th amino acid from the N-terminus is D-Nle, i.e. [D-Nle38]-CRH peptide....
7265157 Sustained release compositions, process for producing the same and use thereof  
Sustained release compositions containing a physiologically active substance or its salt, hydroxynaphthoic acid or its salt and a lactic acid-glycolic polymer or its salt, wherein the product of...
7232798 Neuroprotection and neuroegenisis by administering cyclic prolyl glycine  
The invention relates to the use of cyclic Prolyl Glycine (“cyclic PG” or “cPG”) and analogs and mimetics thereof, as neuroprotective agents for the treatment and or prevention of neurolo...
7192924 Corticotropin releasing factor 2 receptor agonists  
Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular...
7186414 Compounds and compositions for delivering active agents  
Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.
7141546 CRFR2 selective ligands  
CRF peptide analogs that bind to CRFR2 with an affinity far greater than they bind to CRFR1. These analogs exhibit CRF antagonist activity, and they can be based upon the native structures of...
7074408 Use of integrin antagonists to inhibit angiogenesis  
The present invention provides methods and compositions for inhibiting the biological activity of integrins, for inhibiting endothelial cell migration. and for inhibiting angiogenesis. In...
7071161 Variants of corticotropin releasing hormone receptor Type 1 and uses thereof  
The present invention identifies four new isoforms of human corticotropin releasing hormone receptor type 1 (CRH-R1e, 1f, 1g and 1h) and three new isoforms of mouse corticotropin releasing hormone...
6930090 Methods of activating a receptor using amphiphilic drug-oligomer conjugates  
The present invention relates to amphiphilic drug-oligomer conjugates capable of traversing the blood-brain barrier (“BBB”) and to methods of making and using such conjugates. An amphiphilic dru...
6869932 Site-specific preparation of polyethlene glycol-GRF conjugates  
A method is described for the site-specific preparation of hGRF-PEG conjugates containing one or more PEG units (per mole of hGRF) covalently bound to Lys12 and/or Lys21 and/or Nα, characterized ...
6846803 Antagonists specific for the corticotropin-releasing factor receptor type 2 (CRFR2)  
The present invention relates to an antagonist of the ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 8 to 10 N-terminal amino acids of native sauvagine. The...
6803359 Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs  
The glutamic acid residue of corticotropin-releasing hormone analogs have had the position 20 amino acid residue replaced with a D-amino acid moiety. The resulting CRH analogs do not significantly...
6794357 Compositions for inhalation  
Disclosed herein are dry powder compositions comprising a pharmacologically active polypeptide and a surfactant, wherein at least 50% of the total mass of the polypeptide and the surfactant...
6638905 Cloning and recombinant production of CFR receptor(s)  
In accordance with the present invention, there are provided novel G-protein-coupled receptor proteins (CRF-R) characterized by having sufficient binding affinity for corticotropin releasing factor...
6630123 Method to enhance tissue accumulation of radiolabeled compounds  
Administration of a radioisotopic compound by infusion over a period of time greater than two hours, preferably greater than twelve hours, greatly increases the maximum radioactivity that...
6630449 Method for reducing the effect of nicotine addiction and dependancy  
The nicotine addiction associated with smoking can be reduced by a combination of nutrition augmentation, craving reduction, and therapy. The craving reduction is accomplished by administration of...
6623732 Pharmaceutical formulation for nasal administration  
This invention discloses a pharmaceutical formulation for nasal administration which contains a pharmaceutically active polypeptide and a method producing the pharmaceutical formulation. The...
6565879 Topical and transdermal administration of peptidyl drugs with hydroxide-releasing agents as skin permeation enhancers  
A method is provided for increasing the permeability of skin or mucosal tissue to a topically or transdermally administered pharmacologically or cosmeceutically active peptide, polypeptide or...
6544957 Methods and reagents for facilitating transcription  
A previously unknown histone acetylase inhibitor, 6-(1,3-Dioxo-1H, 3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide, termed “scriptaid,” can be used to enhance transcription. Scriptaid can...
6387359 Nonionic surfactant  
Herein are disclosed N-long chain acyl-neutral amino acid polyglycerin esters composed of a polyglycerin having a degree of glycerin polymerization of not smaller than 4 and an N-long chain...
6372713 Anti-depressant effects of corticotropin release inhibiting factor  
Methods and compositions for treatment of depression in animals are provided.
6313088 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents  
Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.
6309633 Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same  
The invention provides a drug-oligomer conjugate having the following general formula: ##STR1##wherein D is a therapeutic drug moiety; H and H' are each a hydrophilic moiety, independently selected...
6303588 Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor  
Methods are disclosed for correcting biological information transfer in a patient in need of such therapy which comprise administration to a patient of a composition comprising a therapeutically...
6291175 Methods for treating a neurological disease by determining BCHE genotype  
Disclosed herein is a method for treating a patient with a neurological disease by determining a patient's BCHE allele status.
6214797 Urocortin peptides, nucleic acid encoding same methods for using same  
Urocortin (Ucn) is a native mammalian peptide generally related to Urotensin I and Corticotropin Releasing Factor (CRF). Human Ucn has the formula:...
6201072 Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties  
A water soluble, biodegradable ABA- or BAB-type tri-block polymer is disclosed that is made up of a major amount of a hydrophobic A polymer block made of a biodegradable polyester and a minor...
6153592 Enhancing the bioavailability of proteolytically labile therapeutic agents  
Proteins or peptidic substances, which may be prepared from naturally occurring proteins, enhance the bioavailability of proteolytically-labile therapeutic agents which, in the absence of the...
6132717 Method for treating mammals having a deficiency in endoprotease  
The invention is based on the finding the furin belongs to a family of endoproteolytically active enzymes and relates to a process in the in vitro cleavage of a protein by treating the protein in...
6071510 Modified amino acids and compositions comprising the same for delivering active agents  
The present invention provides modified amino acids for delivering active agents, and particularly biologically or chemically active agents. The preferred modified amino acids of the present...
6034175 Salts of peptides with carboxy-terminated polyesters  
This invention relates to novel salts composed of a cation derived from a peptide containing at least one basic group and an anion derived from a carboxy-terminated polyester, processes for the...
6020305 Treatment of stress-induced skin disease by corticotropin releasing hormone antagonists and skin mast cell degranulation inhibitors  
A method of reducing or blocking a stress-related atopic skin disease such as exzema or uticaria in a subject comprising administering to the patient an agent that antagonizes CRH-induced...
6001807 Use of CRF-antagonists for treating emesis  
CRF-antagonists are useful in the treatment of emesis.
5981474 Solubilization of pharmaceutical substances in an organic solvent and preparation of pharmaceutical powders using the same  
Provided is a method for preparing a true, homogeneous solution of a pharmaceutical substance dissolved in an organic solvent in which the pharmaceutical substance is not normally soluble....
5976569 Diketopiperazine-based delivery systems  
Compositions useful in the delivery of active agents are provided. These delivery compositions include (a) an active agent; and either (b)(1) a carrier of (i) at least one amino acid and (ii) at...
5968899 Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption  
Disclosed is a medicinal composition, which comprises a peptide as an effective ingredient and as bases, epsilon aminocaproic acid or tranexamic acid and an ethylene oxide-propylene oxide block...
5874227 Cyclic CRF antagonists  
Novel cyclic CRF antagonist peptides have the amino acid sequence: ##STR1## wherein Y is Ac, H, Ac-Thr or H-Thr; R30 is Glu or Cys; R32 is His or preferably a basic and/or aromatic D-amino acid...
5869450 Anti-inflammatory compositions and method with corticotropin-releasing factor analogs  
Peptide analogues are provided with amino acid sequences of the corticotropin-releasing factor superfamily, but having at least one amino acid residue that has been replaced with a D-amino acid...
5855884 Treatment of stress-induced migraine headache with a corticotropin releasing hormone blocker  
Non-traumatic immobilization (restrain) stress causes rapid degranulation of rat dura mast cells, as shown both by light and electron microscopy. These morphologic findings were accompanied by...
Matches 1 - 50 out of 113 1 2 3 >